Filtered By:
Management: National Institutes of Health (NIH)
Therapy: Stem Cell Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 38 results found since Jan 2013.

Spontaneous Recovery of Upper Extremity Motor Impairment After Ischemic Stroke: Implications for Stem Cell-Based Therapeutic Approaches
AbstractPreclinical studies suggest that stem cell therapy (SCT) may improve sensorimotor recovery after stroke. Upper extremity motor impairment (UEMI) is common after stroke, often entailing substantial disability. To evaluate the feasibility of post-stroke UEMI as a target for SCT, we examined a selected sample of stroke patients potentially suitable for SCT, aiming to assess the frequency and recovery of UEMI, as well as its relation to activity limitations and participation restrictions. Patients aged 20 –75 years with first-ever ischemic stroke, and National Institutes of Health Stroke Scale (NIHSS) scores 1–18,...
Source: Translational Stroke Research - February 14, 2017 Category: Neurology Source Type: research

Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study
Publication date: Available online 3 August 2016 Source:The Lancet Author(s): Dheeraj Kalladka, John Sinden, Kenneth Pollock, Caroline Haig, John McLean, Wilma Smith, Alex McConnachie, Celestine Santosh, Philip M Bath, Laurence Dunn, Keith W Muir Background CTX0E03 is an immortalised human neural stem-cell line from which a drug product (CTX-DP) was developed for allogeneic therapy. Dose-dependent improvement in sensorimotor function in rats implanted with CTX-DP 4 weeks after middle cerebral artery occlusion stroke prompted investigation of the safety and tolerability of this treatment in stroke patients. Methods We did ...
Source: The Lancet - August 3, 2016 Category: Journals (General) Source Type: research

Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol
Introduction Stroke is a serious public health problem, given it is a major cause of disability worldwide despite the spread of recanalisation therapies. Enhancement of brain plasticity with stem cell administration is a promising innovative therapy to reduce sequelae in these patients. Methods and analysis We have developed a phase IIb, multicentre, randomised, double-blind, placebo-controlled clinical trial protocol to evaluate the safety and efficacy of intravenous administration of allogeneic adipose tissue-derived mesenchymal stem cells (AD-MSCs) in patients with acute ischaemic stroke, concurrently with conventional...
Source: BMJ Open - August 9, 2021 Category: General Medicine Authors: de Celis-Ruiz, E., Fuentes, B., Moniche, F., Montaner, J., Borobia, A. M., Gutierrez-Fernandez, M., Diez-Tejedor, E. Tags: Open access, Neurology Source Type: research

Comparative Analysis of the Results of Stroke Treatment With Multiple Administrations of Wharton's Jelly Mesenchymal Stem Cells-Derived HE-ATMP and Standard Conservative Treatment: Case Series Study
Cell Transplant. 2023 Jan-Dec;32:9636897231195145. doi: 10.1177/09636897231195145.ABSTRACTStroke remains still the leading cause of long-term disability worldwide. Although interventions such as early reperfusion, intravenous thrombolysis, and endovascular revascularization have shown neurological benefit in stroke patients, there is still lack of effective treatment enabling regeneration of nervous tissue after cerebral ischemic episodes. Cell therapy is an evolving opportunity for stroke survivors with residual neurological deficits. The purpose of this study was to evaluate safety and potential efficacy of multiple admi...
Source: Cell Transplantation - August 30, 2023 Category: Cytology Authors: Olga Milczarek Jakub Swad źba Patrycja Swad źba Anna Starowicz-Filip Roger M Krzy żewski Stanis ław Kwiatkowski Marcin Majka Source Type: research

Final Results of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS): A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Pilot Clinical Trial
We report the final trial results after 24 months of follow-up. Recruitment began in December 2014 and stopped in December 2017 after 19 of 20 planned patients were included. Six patients did not receive study treatment: two due to technical issues and four for acquiring exclusion criteria after randomization. The final study sample was composed of 13 patients (4 receiving AD-MSCs and 9 placebo). One patient in the placebo group died within the first week after study treatment delivery due to sepsis. Two non-treatment-related serious AEs occurred in the AD-MSC group and nine in the placebo group. The total number of AEs an...
Source: Cell Transplantation - March 18, 2022 Category: Cytology Authors: Elena de Celis-Ruiz Blanca Fuentes Mar ía Alonso de Leciñana Mar ía Gutiérrez-Fernández Alberto M Borobia Raquel Guti érrez-Zúñiga Gerardo Ruiz-Ares Laura Otero-Ortega Fernando Laso-Garc ía Mari Carmen G ómez-de Frutos Exuperio D íez-Tejedor Source Type: research

Efficacy and safety of human-derived neural stem cell in patients with ischaemic stroke: study protocol for a randomised controlled trial
Introduction Stroke is the most common cause of neurological disability in adults worldwide. Neural stem cell (NSC) transplantation has shown promising results as a treatment for stroke in animal experiments. The pilot investigation of stem cells in stroke phase 1 and phase 2 trials showed that transplantation of the highest dose (20 million cells) was well tolerated. Preliminary clinical benefits have also been observed. However, the trials were open-label and had a small sample size. Furthermore, human NSCs (hNSCs) were intracerebrally implanted, and some serious adverse events were considered to be related to the surgic...
Source: BMJ Open - November 8, 2022 Category: General Medicine Authors: Xie, C., Wang, K., Peng, J., Jiang, X., Pan, S., Wang, L., Wu, Y., Guan, Y. Tags: Open access, Neurology Source Type: research

Intracerebral Implantation of Autologous Peripheral Blood Stem Cells in Stroke Patients: a Randomized Phase II Study.
Abstract In our previous study, intracerebral implantation of peripheral blood stem cells (PBSC) improved functional outcome in rats with chronic cerebral infarction. Based on this findings, a randomized, single blind controlled study was conducted in 30 patients [PBSC group (n=15) and control group (n=15)] with middle cerebral artery infarction confirmed on T2?weighted MRI 6 months to 5 years after a stroke. Only subjects with neurological deficits of intermediate severity based on the National Institute of Health Stroke Scale (NIHSS) (range: 9?20) that had been stable for at least 3 months were enrolled. Those i...
Source: Cell Transplantation - January 29, 2014 Category: Cytology Authors: Chen DC, Lin SZ, Fan JR, Lin CH, Lee W, Lin CC, Liu YJ, Tsai CH, Chen JC, Cho DY, Lee CC, Shyu WC Tags: Cell Transplant Source Type: research

A two-year follow-up study of co-transplantation with neural stem/precursor cells and mesenchymal stromal cells in ischemic stroke patients.
Abstract Stem cell therapy is an emerging therapeutic modality in the treatment of stroke. We assessed the safety and feasibility of the co-transplantation of neural stem/precursor cells (NSPCs) and mesenchymal stromal cells (MSCs) in patients with ischemic stroke. Eight patients were enrolled in this study. All patients had a hemisphere with infarct lesions located on one side of the territories of the cerebral middle or anterior arteries as revealed with cranial magnetic resonance imaging (MRI). The patients received one of the following two types of treatment: the first treatment involved 4 intravenous injectio...
Source: Cell Transplantation - October 20, 2014 Category: Cytology Authors: Qiao LY, Huang FJ, Zhao M, Xie JH, Shi J, Wang J, Lin XZ, Zuo H, Wang YL, Geng TC Tags: Cell Transplant Source Type: research

Complete Restoration of Motor Function in Acute Cerebral Stroke Treated with Allogeneic Human Umbilical Cord Blood Monocytes: Preliminary Results of a phase I Clinical Trial
Cell Transplant. 2021 Jan-Dec;30:9636897211067447. doi: 10.1177/09636897211067447.ABSTRACTStem cell therapy has been explored for the treatment of cerebral stroke. Several types of stem cells have been investigated to ensure the safety and efficacy in clinical trials.Cryopreserved umbilical cord blood (UCB) mononuclear cells (MNCs) obtained from healthy donors have a more stabilized quality, thereby ensuring a successful therapy. A phase I study was conducted on patients aged 45-80 years who sustained acute ischemic stroke. An UCB unit was obtained from a public cord blood bank based on ABO/Rh blood type, HLA matching scor...
Source: Cell Transplantation - December 23, 2021 Category: Cytology Authors: Tian-Kuo Lee Cheng-You Lu Sheng-Tzung Tsai Pao-Hui Tseng Yu-Chen Lin Shinn-Zong Lin Jonas C Wang Chih-Yang Huang Tsung-Lang Chiu Source Type: research